Portzamparc Initiates the Coverage of Pherecydes Pharma
28 Aprile 2021 - 7:00AM
Business Wire
Regulatory News:
Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a
biotechnology company specializing in precision phage therapy to
treat resistant and/or complicated bacterial infections, today
announces the publication of an initiation report by Portzamparc, a
leading research firm in the small and mid-cap segment in
France.
Portzamparc initiates the coverage of Pherecydes Pharma with a
target price at €11.10 per share and a “Buy” recommendation*.
* The investment recommendation was made on April 22, 2021 -
9:22 am (GMT+1) and was first released on April 22, 2021 - 9:28 am
(GMT+1). This information does not constitute an offer to sell or
subscribe, or the solicitation of an order to buy or subscribe for
securities in France, Europe, the US or any other country.
About Portzamparc
Subsidiary of the BNP Paribas Group, Portzamparc is an
Investment Services Provider, approved and regulated by the
Autorité des Marchés Financiers, specializing in the Small &
Mid-Caps segment, which covers a range of more than 150 listed
companies through its Research Department.
Portzamparc is also a major player in Small & Mid-Caps
financial transactions, with several hundred SMEs and SMIs
supported in financing their growth via the stock market.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company
that develops treatments against resistant bacterial infections,
responsible for many serious infections. The Company has developed
an innovative approach, precision phage therapy, based on the use
of phages, natural bacteria-killing viruses. Pherecydes Pharma is
developing a portfolio of phages targeting 3 of the most resistant
and dangerous bacteria, which alone account for more than two
thirds of hospital-acquired resistant infections: Staphylococcus
aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of
precision phage therapy has been successfully applied in 26
patients in the context of compassionate use, under the supervision
of the French National Agency for the Safety of Medicines (ANSM).
Headquartered in Nantes, Pherecydes Pharma has a team of around
twenty experts from the pharmaceutical industry, biotechnology
sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
Pherecydes Pharma and Portzamparc have signed an analysis
service agreement through which Portzamparc has undertaken to
produce and distribute investment research studies on Pherecydes
Pharma. In addition, Portzamparc has been Lead Manager in a public
offering of Pherecydes Pharma's financial instruments during the
last twelve months and has signed a liquidity contract with
Pherecydes Pharma.
This press release contains non-factual elements, including, but
not limited to, certain statements regarding future results and
other future events. These statements are based on the current
vision and assumptions of the management of the Company. They
incorporate known and unknown risks and uncertainties that could
result in significant differences in results, profitability and
expected events. In addition, Pherecydes Pharma, its shareholders
and its affiliates, directors, officers, counsels and employees
have not verified the accuracy of, and make no representations or
warranties about, statistical information or forecast information
contained within this news release and that originates or is
derived from third party sources or industry publications; these
statistical data and forecast information are only used in this
press release for information purposes. Finally, this press release
may be drafted in French and in English. In the event of
differences between the two texts, the French version will
prevail.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427006029/en/
Pherecydes Pharma Philippe Rousseau CFO
investors@pherecydes-pharma.com
NewCap Dusan Oresansky Investor Relations
pherecydes@newcap.eu T.: +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations pherecydes@newcap.eu T.:
+33 1 44 71 94 98